<DOC>
	<DOCNO>NCT02400281</DOCNO>
	<brief_summary>This open label , two-arm , Phase I-II trial , non-randomized . Arm 1 : crenolanib standard chemotherapy ( Idarubicin/Cytarabine , MEC ; Mitoxantrone/Etoposide/Cytarabine , FLAG-Ida : Fludarabine/Cytarabine/G-CSF/Idarubicin ) Arm 2 : crenolanib 5-azacitidine</brief_summary>
	<brief_title>Study Crenolanib Combined With Chemotherapy FLT3-mutated Acute Myeloid Leukemia Patients</brief_title>
	<detailed_description>For arm : The phase I dose-limiting toxicity ( DLT ) determination use 3+3 design . Phase II total 52 patient ( 26 per arm ) treat established phase I dose . Enrollment simultaneous arm .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Crenolanib</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Confirmed diagnosis refractory/relapsed AML highrisk MDS Arm 1 : Subjects must receive least one prior therapy maximum three prior therapy Arm 2 : Subjects must receive least one prior therapy maximum three prior therapy . No prior treatment 5Azacitidine allow arm . 2 . FLT3 mutation positive ( ITD , TKD ) 3 . ECOG PS 02 4 . Adequate liver renal function 5 . Negative pregnancy test 6 . Extramedullary leukemia allow except CNS disease Arm 1 2 Exclusion : 1 . &lt; 5 % blast marrow blood time screen 2 . Active HIV , hepatitis B C 3 . CNS leukemia 4 . Clinically significant GVHD organ dysfunction chemotherapy specify protocol give 5 . Patient AMLM3 ( APL ) 6 . Preexisting liver disease ( i.e . cirrhosis , chronic hepatitis B C , nonalcoholic steatohepatitis , sclerosing cholangitis )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>